Finanzen von Utah Medical Products Inc (UTMD)UTMDUtah Medical Products Inc

Utah Medical Products Inc (UTMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Gynecology/Electrosurgery/Urology, accounting for 50.2% of total sales, equivalent to $4.28M. Other significant revenue streams include Neonatal and Blood Pressure Monitoring and Accessories. Understanding this composition is critical for investors evaluating how UTMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Utah Medical Products Inc maintains a gross margin of 56.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.42%, while the net margin is 32.33%. These profitability ratios, combined with a Return on Equity (ROE) of 8.81%, provide a clear picture of how effectively UTMD converts its operational activities into shareholder value.

In the context of the broader market, UTMD competes directly with industry leaders such as ELMD and TLSI. With a market capitalization of $229.63M, it holds a significant position in the sector. When comparing efficiency, UTMD's gross margin of 56.14% stands against ELMD's 78.71% and TLSI's 86.78%. Such benchmarking helps identify whether Utah Medical Products Inc is trading at a premium or discount relative to its financial performance.

The company has shown stable financial performance with a gross margin of 56.14% in the latest quarter and a net margin of 32.33%. However, total revenue has declined by 10.2% year-over-year in Q1, raising concerns about market demand.